rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2018-785-790rsp-2658Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSТоксический эпидермальный некролиз как вариант тяжелого поражения кожи при системной красной волчанкеToxic epidermal necrolysis as a variant of severe skin lesions in systemic lupus erythematosusВоробьеваЛ. Д.VorobyevaL. D.

115522 Москва, Каширское шоссе, 34А.

34A, Kashirskoe Shosse, Moscow 115522.

evagolland@gmail.comАсееваЕ. А.AseevaE. A.

115522 Москва, Каширское шоссе, 34А.

34A, Kashirskoe Shosse, Moscow 115522.

СоловьевС. К.SolovyevS. K.

115522 Москва, Каширское шоссе, 34А.

34A, Kashirskoe Shosse, Moscow 115522.

БелоусоваТ. А.BelousovaT. A.

119991 Москва, ул. Трубецкая, 8, стр. 2.

8, Trubetskaya St., Build. 2, Moscow 119991.

ЛопатинаН. Е.LopatinaN. E.

115522 Москва, Каширское шоссе, 34А.

34A, Kashirskoe Shosse, Moscow 115522.

СажинаЕ. Г.SazhinaE. G.

115522 Москва, Каширское шоссе, 34А.

34A, Kashirskoe Shosse, Moscow 115522.

СериковаГ. В.SerikovaG. V.

115522 Москва, Каширское шоссе, 34А.

34A, Kashirskoe Shosse, Moscow 115522.

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой».РоссияV.A. Nasonova Research Institute of Rheumatology.Russian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), кафедра кожных и венерических болезней.РоссияDepartment of Skin and Venereal Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia.Russian Federation201822012019566785790Copyright © Воробьева Л.Д., Асеева Е.А., Соловьев С.К., Белоусова Т.А., Лопатина Н.Е., Сажина Е.Г., Серикова Г.В., 20192019Воробьева Л.Д., Асеева Е.А., Соловьев С.К., Белоусова Т.А., Лопатина Н.Е., Сажина Е.Г., Серикова Г.В.Vorobyeva L.D., Aseeva E.A., Solovyev S.K., Belousova T.A., Lopatina N.E., Sazhina E.G., Serikova G.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2658

Долгое время считали, что токсический эпидермальный некролиз (ТЭН) – это тяжелейшее проявление лекарственной аллергии. Однако в конце 70-х годов прошлого века были впервые описаны кожные изменения при системной красной волчанке (СКВ) в виде ТЭН. В настоящее время в англоязычной литературе опубликованы сообщения о 30 случаях такого поражения при СКВ. Нами представлено клиническое наблюдение ТЭН как непосредственного проявления СКВ; впервые в отечественной клинической практике при данном состоянии описан положительный опыт применения не только внутривенного иммуноглобулина, но и ритуксимаба с хорошим терапевтическим эффектом.

Toxic epidermal necrolysis (TEN) has been long believed to be the most severe manifestation of drug allergy. However, cutaneous changes as TEN in systemic lupus erythematosus (SLE) were first described in the late 1970s. As of now, the English-language literature published reports of 30 cases of such lesions in SLE. This paper describes a clinical case of TEN as a direct manifestation of SLE; the positive experience has been first depicted in using not only intravenous immunoglobulin, but also rituximab with a good therapeutic effect in Russian clinical practice.

токсический эпидермальный некролизсистемная красная волчанкаклиническое наблюдениевнутривенный иммуноглобулинритуксимабtoxic epidermal necrolysissystemic lupus erythematosusclinical caseintravenous immunoglobulinrituximabReferencesRoujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-85. doi: 10.1056/NEJM199411103311906Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-85. doi: 10.1056/NEJM199411103311906Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens – Johnson syndrome, toxic epidermal ecrolysis and hypersensitivity syndrome. Dermatol Online J. 2002;8(1):5.Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens – Johnson syndrome, toxic epidermal ecrolysis and hypersensitivity syndrome. Dermatol Online J. 2002;8(1):5.Letko E, Papaliodis GN, Daoud YJ, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allerg Asthma Immunol. 2005;94(4):419-36. doi: 10.1016/S1081-1206(10)61112-XLetko E, Papaliodis GN, Daoud YJ, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allerg Asthma Immunol. 2005;94(4):419-36. doi: 10.1016/S1081-1206(10)61112-XSharma VK, Jerajani HR, Srinivas CR, et al. Proposed IADVL Consensus Guidelines 2006: Management of Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). New Delhi: IADVL's Therapeutic Guidelines Committee; 2008.Sharma VK, Jerajani HR, Srinivas CR, et al. Proposed IADVL Consensus Guidelines 2006: Management of Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). New Delhi: IADVL's Therapeutic Guidelines Committee; 2008.Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome and toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-9. doi: 10.1056/NEJM199512143332404Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome and toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-9. doi: 10.1056/NEJM199512143332404Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153(2):241-53. doi: 10.1111/j.1365-2133.2005.06721.xChave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153(2):241-53. doi: 10.1111/j.1365-2133.2005.06721.xRaj D, Brash DE, Grossman D. Keratinocyte apoptosis in epidermal development and disease. J Investigat Dermatol. 2006;126:243-57. doi: 10.1038/sj.jid.5700008Raj D, Brash DE, Grossman D. Keratinocyte apoptosis in epidermal development and disease. J Investigat Dermatol. 2006;126:243-57. doi: 10.1038/sj.jid.5700008Leaute-Labreze C, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of erythema multiforme and Stevens–Johnson syndrome. Arch Dis Child. 2000;83:347-52. doi: 10.1136/adc.83.4.347Leaute-Labreze C, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of erythema multiforme and Stevens–Johnson syndrome. Arch Dis Child. 2000;83:347-52. doi: 10.1136/adc.83.4.347Harr T, French LE. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphan J Rare Dis. 2010;5:39-40. doi: 10.1186/1750-1172-5-39Harr T, French LE. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphan J Rare Dis. 2010;5:39-40. doi: 10.1186/1750-1172-5-39Жерносек ВФ, Дюбкова ТП. Синдром Стивенса–Джонсона – токсический эпидермальный некролиз у детей. Часть I. Определение, этиология, патогенез, клинические проявления, системное лечение. Педиатрическая фармакология. 2011;8(1):30-8 [Zhernosek VF, Dyubkova TP. Stevens-Johnson syndrome – toxic epidermal necrolysis in children. Part I. Definition, etiology, pathogenesis, clinical manifestations, systemic treatment. Pediatricheskaya Farmakologiya. 2011;8(1):30-8 (In Russ.)].Жерносек ВФ, Дюбкова ТП. Синдром Стивенса–Джонсона – токсический эпидермальный некролиз у детей. Часть I. Определение, этиология, патогенез, клинические проявления, системное лечение. Педиатрическая фармакология. 2011;8(1):30-8 [Zhernosek VF, Dyubkova TP. Stevens-Johnson syndrome – toxic epidermal necrolysis in children. Part I. Definition, etiology, pathogenesis, clinical manifestations, systemic treatment. Pediatricheskaya Farmakologiya. 2011;8(1):30-8 (In Russ.)].Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens–Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62:527-31. doi: 10.1111/j.1398-9995.2006.01295.xYip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens–Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62:527-31. doi: 10.1111/j.1398-9995.2006.01295.xGilliam JN, Sontheimer RD. Skin manifestations of SLE [Review]. Clin Rheum Dis. 1982;8:207-18.Gilliam JN, Sontheimer RD. Skin manifestations of SLE [Review]. Clin Rheum Dis. 1982;8:207-18.Sontheimer RD. Subacute cutaneous lupus erythematosus. Clin Dermatol. 1985;3:58-68. doi: 10.1016/0738-081X(85)90078-1Sontheimer RD. Subacute cutaneous lupus erythematosus. Clin Dermatol. 1985;3:58-68. doi: 10.1016/0738-081X(85)90078-1Lerch M, Mainetti C, Terziroli Beretta-Piccoli B. Current Perspectives on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allerg Immunol. 2017 Nov 29;54(1):147-76. doi: 10.1007/s12016-017-8654-zLerch M, Mainetti C, Terziroli Beretta-Piccoli B. Current Perspectives on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allerg Immunol. 2017 Nov 29;54(1):147-76. doi: 10.1007/s12016-017-8654-zGilliam IN. The cutaneous signs of lupus erythematosus. Contin Educ Fam Phys. 1977;6:34-70.Gilliam IN. The cutaneous signs of lupus erythematosus. Contin Educ Fam Phys. 1977;6:34-70.Sayag J, Mongin M, Weiller PJ, et al. Toxic epidermic necrolysis in acute disseminated lupus erythematosus. Ann Dermatol Venereol. 1980;107(11):1077-81.Sayag J, Mongin M, Weiller PJ, et al. Toxic epidermic necrolysis in acute disseminated lupus erythematosus. Ann Dermatol Venereol. 1980;107(11):1077-81.Chan HL. Observations on drug-induced toxic epidermal necrolysis in Singapore. J Am Acad Dermatol. 1984;10(6):973-8. doi: 10.1016/S0190-9622(84)80317-5Chan HL. Observations on drug-induced toxic epidermal necrolysis in Singapore. J Am Acad Dermatol. 1984;10(6):973-8. doi: 10.1016/S0190-9622(84)80317-5Burge SM, Dawber RP. Stevens–Johnson syndrome and toxic epidermal necrolysis in a patient with systemic lupus erythematosus [letter]. J Am Acad Dermatol. 1985;13:665-6. doi: 10.1016/S0190-9622(85)80447-3Burge SM, Dawber RP. Stevens–Johnson syndrome and toxic epidermal necrolysis in a patient with systemic lupus erythematosus [letter]. J Am Acad Dermatol. 1985;13:665-6. doi: 10.1016/S0190-9622(85)80447-3Bielsa I, Herrero C, Font J, Mascaro JM. Lupus erythematosus and toxic epidermal necrolysis [letter]. J Am Acad Dermatol. 1987;16(6):1265-7. doi: 10.1016/S0190-9622(87)80031-2Bielsa I, Herrero C, Font J, Mascaro JM. Lupus erythematosus and toxic epidermal necrolysis [letter]. J Am Acad Dermatol. 1987;16(6):1265-7. doi: 10.1016/S0190-9622(87)80031-2Ting W, Stone M, Racila D, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004;13(12):941-50. doi: 10.1191/0961203304lu2037saTing W, Stone M, Racila D, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004;13(12):941-50. doi: 10.1191/0961203304lu2037saMutasim DF. Severe subacute cutaneous lupus erythematosus presenting with generalized erythroderma and bullae. J Am Acad Dermatol. 2003;48:947-9. doi: 10.1067/mjd.2003.244Mutasim DF. Severe subacute cutaneous lupus erythematosus presenting with generalized erythroderma and bullae. J Am Acad Dermatol. 2003;48:947-9. doi: 10.1067/mjd.2003.244Kelly JP, Auquier A, Rzany B, et al. An international collaborative casecontrol study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol. 1995;48:1099-108. doi: 10.1016/0895-4356(95)00004-NKelly JP, Auquier A, Rzany B, et al. An international collaborative casecontrol study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol. 1995;48:1099-108. doi: 10.1016/0895-4356(95)00004-NMaldelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: A novel manifestation of lupus? J Am Acad Dermatol. 2003;48:525-9. doi: 10.1067/mjd.2003.107Maldelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: A novel manifestation of lupus? J Am Acad Dermatol. 2003;48:525-9. doi: 10.1067/mjd.2003.107Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctivebut immunologically heterogeneous bullous disorder. J Invest Dermatol. 1993;100:285-345. doi: 10.1111/1523-1747.ep12355210Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctivebut immunologically heterogeneous bullous disorder. J Invest Dermatol. 1993;100:285-345. doi: 10.1111/1523-1747.ep12355210Махнева НВ, Давиденко ЕБ, Белецкая ЛВ. О проблеме диагностики и дифференциальной диагностики аутоиммунной пузырчатки. Альманах клинической медицины. 2014;34:9-14 [Makhneva NV, Davidenko EB, Beletskaya LV. On the problem of diagnosis and differential diagnosis of autoimmune pemphigus. Al'manakh Klinicheskoy Meditsiny. 2014;34:9-14 (In Russ.)].Махнева НВ, Давиденко ЕБ, Белецкая ЛВ. О проблеме диагностики и дифференциальной диагностики аутоиммунной пузырчатки. Альманах клинической медицины. 2014;34:9-14 [Makhneva NV, Davidenko EB, Beletskaya LV. On the problem of diagnosis and differential diagnosis of autoimmune pemphigus. Al'manakh Klinicheskoy Meditsiny. 2014;34:9-14 (In Russ.)].Yung A, Oakley A. Bullous systemic lupus erythematosus. Australas J Dermatol. 2000;41(4):234-7. doi: 10.1046/j.1440-0960.2000.00426.xYung A, Oakley A. Bullous systemic lupus erythematosus. Australas J Dermatol. 2000;41(4):234-7. doi: 10.1046/j.1440-0960.2000.00426.xViard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-3. doi: 10.1126/science.282.5388.490Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-3. doi: 10.1126/science.282.5388.490Kazatchkine MD, Kaveri SV. Advances in immunology: immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747-55. doi: 10.1056/NEJMra993360Kazatchkine MD, Kaveri SV. Advances in immunology: immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747-55. doi: 10.1056/NEJMra993360French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding. Int Immunopharmacol. 2006;6:543-9. doi: 10.1016/j.intimp.2005.11.012French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding. Int Immunopharmacol. 2006;6:543-9. doi: 10.1016/j.intimp.2005.11.012Fine JD. Management of acquired bullous skin diseases. N Engl J Med. 1995;333(22):1475-84. doi: 10.1056/NEJM199511303332207Fine JD. Management of acquired bullous skin diseases. N Engl J Med. 1995;333(22):1475-84. doi: 10.1056/NEJM199511303332207Roujeau JC, Stern RS. Medical progress: severe adverse cutaneous reactions to drugs. NEJM. 1994;331(19):1272-85. doi: 10.1056/NEJM199411103311906Roujeau JC, Stern RS. Medical progress: severe adverse cutaneous reactions to drugs. NEJM. 1994;331(19):1272-85. doi: 10.1056/NEJM199411103311906

The authors declare that there are no conflicts of interest present.